Delta variant continues to be dominant in Covid cases across India: INSACOG

The Delta variant of SARS-CoV2 continues to be dominant lineage for new cases across the country, while the other Variants of Concern (VoC) are at a lower rate and declining, INSACOG said.

coronavirus
A beneficiary receives Covid-19 vaccine dose, in Patna | (PTI Photo)
Press Trust of India New Delhi
3 min read Last Updated : Jul 22 2021 | 3:32 PM IST

The Delta variant of SARS-CoV2 continues to be the dominant lineage for new cases across the country, while the other Variants of Concern (VoC) are at a lower rate and declining, INSACOG, a consortium of government panels involved in the genome-sequencing of the coronavirus, has said.

There is currently no evidence of any new Delta sub-lineage that is of greater concern than Delta, it has said.

"Delta continues to be the dominant lineage for new cases across all parts of India in recent samples and remains the most rapidly rising lineage globally that is responsible for multiple outbreaks, including across Southeast Asia, which shows the fastest growth in new cases globally," the INSACOG said.

Regions with high vaccination and strong public health measures, such as Singapore, continue to do well, it noted.

The Delta variant was behind the deadly second wave of the coronavirus in India that killed thousands and infected lakhs during March to May.

The INSACOG said a study by the Indian Council of Medical Research (ICMR) has confirmed that most of the clinical cases in vaccine breakthrough were infected with the Delta variant but only 9.8 per cent cases required hospitalisation, while fatality was found to be restricted to 0.4 per cent.

It added that the data for higher infectivity of Delta continues to grow with the secondary attack rate in household contacts being almost double for Delta, when compared to Alpha (Public Health England, July 9 update). The other VoC continue to be very low in India and are declining relative to Delta globally.

"Public health measures to reduce transmission and vaccination remain critical," the INSACOG stressed.

No cases of the Lambda variant have so far been reported in the country, it added.

In data from the UK, Lambda is still seen primarily in travellers or their contacts and is not growing relative to Delta.

A growing spectrum of mutations is seen in the Delta background in the UK, the US and India.

The most frequent spike protein mutations, other than K417N (AY.1/AY.2), seen in the UK are G446V and P251L. In India, A222V and K77T have been reported as possible markers of sub-lineages.

Previous research into the A222V mutation for either transmissibility or immune escape was negative. In case of the K77T mutation, it has previously been reported in a cluster of Delta that spread to Asiatic lions in a zoo, and seen in sequences from Tamil Nadu, but has no known impact on transmission or immune escape in humans, the INSACOG said.

The Indian SARS-CoV-2 Genomics Consortium (INSACOG), jointly initiated by the Union Ministry of Health and the Department of Biotechnology (DBT) with the Council for Scientific and Industrial Research (CSIR) and the ICMR, is a consortium of 28 national laboratories to monitor the genomic variations in SARS-CoV-2.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusDelta variant of coronavirusCoronavirus Vaccine

First Published: Jul 22 2021 | 3:32 PM IST

Next Story